Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 155

1.

Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer.

Gurda GT, Ambros T, Nikiforova MN, Nikiforov YE, Lucas PC, Dabbs DJ, Lee AV, Brufsky AM, Puhalla SL, Bhargava R.

Appl Immunohistochem Mol Morphol. 2016 Feb 9. [Epub ahead of print]

PMID:
26862949
2.

Biomarker assessment and molecular testing for prognostication in breast cancer.

Kos Z, Dabbs DJ.

Histopathology. 2016 Jan;68(1):70-85. doi: 10.1111/his.12795. Review.

PMID:
26768030
3.

Phyllodes tumours of the breast: a consensus review.

Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, Calvo JP, Dabbs DJ, Ellis IO, Eusebi V, Farshid G, Fox SB, Ichihara S, Lakhani SR, Rakha EA, Reis-Filho JS, Richardson AL, Sahin A, Schmitt FC, Schnitt SJ, Siziopikou KP, Soares FA, Tse GM, Vincent-Salomon A, Tan PH.

Histopathology. 2016 Jan;68(1):5-21. doi: 10.1111/his.12876. Review.

PMID:
26768026
4.

Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management.

Rakha EA, Badve S, Eusebi V, Reis-Filho JS, Fox SB, Dabbs DJ, Decker T, Hodi Z, Ichihara S, Lee AH, Palacios J, Richardson AL, Vincent-Salomon A, Schmitt FC, Tan PH, Tse GM, Ellis IO.

Histopathology. 2016 Jan;68(1):45-56. doi: 10.1111/his.12861. Review.

PMID:
26348644
5.

Developing in vitro models of human ductal carcinoma in situ from primary tissue explants.

Brown DD, Dabbs DJ, Lee AV, McGuire KP, Ahrendt GM, Bhargava R, Davidson NE, Brufsky AM, Johnson RR, Oesterreich S, McAuliffe PF.

Breast Cancer Res Treat. 2015 Sep;153(2):311-21. doi: 10.1007/s10549-015-3551-8. Epub 2015 Aug 18.

PMID:
26283301
6.
7.

Molecular drivers of lobular carcinoma in situ.

Logan GJ, Dabbs DJ, Lucas PC, Jankowitz RC, Brown DD, Clark BZ, Oesterreich S, McAuliffe PF.

Breast Cancer Res. 2015 Jun 4;17:76. doi: 10.1186/s13058-015-0580-5. Review.

8.

Dual HER2 gene protein assay: focused study of breast cancers with 2+ immunohistochemical expression.

Li Z, Dabbs DJ, Cooper KL, Bhargava R.

Am J Clin Pathol. 2015 Mar;143(3):451-8. doi: 10.1309/AJCPKIVVW4OBPX6I.

PMID:
25696805
9.

Immunohistochemical profile of breast cancer with respect to estrogen receptor and HER2 status.

Gloyeske NC, Woodard AH, Elishaev E, Yu J, Clark BZ, Dabbs DJ, Bhargava R.

Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):202-8. doi: 10.1097/PAI.0000000000000076.

PMID:
25356941
10.

Simultaneous breast and axillary recurrence in a patient with a history of breast cancer and ipsilateral upper extremity melanoma: challenges in diagnosis and management.

Ross M, Hadzikadic Gusic L, Dabbs DJ, Kelley J, Diego E.

Tumori. 2014 Jul-Aug;100(4):136e-9e. doi: 10.1700/1636.17928.

PMID:
25296604
11.

Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas.

Clark BZ, Beriwal S, Dabbs DJ, Bhargava R.

Am J Clin Pathol. 2014 Jul;142(1):64-71. doi: 10.1309/AJCP8H2VBDSCIOBF.

12.
13.

Low ER+ breast cancer: Is this a distinct group?

Gloyeske NC, Dabbs DJ, Bhargava R.

Am J Clin Pathol. 2014 May;141(5):697-701. doi: 10.1309/AJCP34CYSATWFDPQ.

14.

Metastatic Tumors of Unknown Origin: Ancillary Testing in Cytologic Specimens.

Monaco SE, Dabbs DJ.

Surg Pathol Clin. 2014 Mar;7(1):105-29. doi: 10.1016/j.path.2013.10.004. Review.

PMID:
26839272
15.

Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.

Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S.

Cancer Res. 2014 Mar 1;74(5):1463-74. doi: 10.1158/0008-5472.CAN-13-2779. Epub 2014 Jan 14.

16.

Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.

Gao FF, Dabbs DJ, Cooper KL, Bhargava R.

Am J Clin Pathol. 2014 Jan;141(1):102-10. doi: 10.1309/AJCP6CXS8OSRHXIR.

17.

Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry.

Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Lakhani SR, Palacios J, Rakha E, Richardson AL, Schmitt FC, Tan PH, Tse GM, Vincent-Salomon A, Ellis IO, Badve S, Reis-Filho JS.

Am J Surg Pathol. 2013 Jul;37(7):e1-11. doi: 10.1097/PAS.0b013e3182918a2b. Review.

PMID:
23759937
18.

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.

Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, Bhargava R.

Mod Pathol. 2013 May;26(5):658-64. doi: 10.1038/modpathol.2013.36. Epub 2013 Mar 15.

19.

Cancer of unknown primary origin: using ancillary techniques with caution.

Bhargava R, Dabbs DJ.

J Clin Oncol. 2013 Apr 10;31(11):1478-9. doi: 10.1200/JCO.2012.46.9056. Epub 2013 Feb 25. No abstract available.

20.

Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.

Jones MW, Onisko A, Dabbs DJ, Elishaev E, Chiosea S, Bhargava R.

Int J Gynecol Cancer. 2013 Feb;23(2):380-4. doi: 10.1097/IGC.0b013e31825cc8ee.

PMID:
23318908
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk